Clinical reversal of the multidrug resistance phenotype: True tumour modulation or pharmacokinetic interaction?
- 1 January 1994
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 30 (14) , 2039-2041
- https://doi.org/10.1016/0959-8049(94)00423-3
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Multidrug Resistance: Clinical Opportunities in Diagnosis and CircumventionHematology/Oncology Clinics of North America, 1994
- Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.Journal of Clinical Oncology, 1994
- Paclitaxel (Taxol)Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1994
- Modulation of multidrug resistance: at the threshold.Journal of Clinical Oncology, 1993
- P glycoprotein (P-gp) and drug resistance – time for reappraisal?British Journal of Cancer, 1993
- Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients.Journal of Clinical Oncology, 1993
- Pharmacologic interactions between the resistance‐modifying cyclosporine sdz psc 833 and etoposide (VP 16–213) enhance In Vivo cytostatic activity and toxicityInternational Journal of Cancer, 1992
- Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenograftsBiochemical Pharmacology, 1989
- Effects of verapamil on the pharmacokinetics of daunomycin in the ratCancer Chemotherapy and Pharmacology, 1987
- The effect of verapamil on the pharmacokinetics of adriamycinCancer Chemotherapy and Pharmacology, 1986